DERMAL FILLER PRODUCT COMPARISON Manufacturer Product(s) Description Physician Regulatory Status Component ABR-Development
Tricalcium phosphate suspended in hyaluron-
12 mg/ml; for medium wrinkles and lip contour.
18 mg/ml; for deep wrinkles and volume. 27 mgl/ml; for volume augmentation andfacial contouring.
Purified, medical grade polydimethylsiloxane
Laboratories, Inc.
oil – 1000 cs. For microdroplet injection.
FDA for retinal detachments,but not for facial filler indica-tions. Off label use only. Allergan
Purified bovine-based collagen 35 mg/ml x 6.
Purified bovine-based collagen 65 mg/ml x 6.
cross-linked with glutaraldehyde x 6. *All collagen products contain 0.3% lidocaine.
Purified human-based collagen 35 mg/ml.
*All collagen products contain 0.3% lidocaine.
Non-animal, cross-linked cohesive hyaluronic
Non-animal, cross-linked cohesive hyaluronic
Non-animal, cross-linked cohesive hyaluronic
Non-animal, cross-linked cohesive hyaluronic
Non-animal, cross-linked cohesive hyaluronic
acid 24 mg/g. *All Juvéderm ULTRA products contain 0.3%lidocaine.
Non-animal, cross-linked cohesive hyaluronic
Anteis S.A.
Non-animal 5 phase cross-linked hyaluronic
CE mark. Pending approval inCanada and South Korea. Artes Medical
20% polymethylmethacrylate (PMMA) – 30 to
50 microns – 80% purified bovine collagen
55.7%) microspheres, 25 – 45 microns, sus-pended in an aquaeous polysaccharide gel(1.3% sodium carboxymethylcellulose USP,6.4% glycerin USP & 36.6% water USP). BioForm Medical
Generation polyacrylamide gel comprised of
(Russia) BioPolymer
MATRIDEX: synthetic hyaluronic acid sodium
GmbH & Co. KG
salt 25 mg, hypromellose 15 mg, positively
charged DEAE sephadex particles 25 mg(cross-linked dextran). MATRIDUR: synthetic stabalized hyaluronic acidsodium salt 25 mg and hypromellose 5 mg. MATRIGEL: stabalized HA 12.25 mg.
2.5% cross-linked hydrophilic polyacrylamide
International A/S
trials under way. For investiga-tional use only in U.S. CE mark-ing: CE 0543 – March 2001. Sold in more than 30 countriesaround the world. Dermabiol Institute of
Rhegecoll: 40% bovine collagen from U.S. Kuhra Vital
(stem cell) 10% polymethacrylate, 15%copolymer 4-G, 15% stabilizer / emulsifier. Dermatech
acrylic hydrogel (hydroxyethylmetacrylate –
HEMA and ethylmetacrylate (EMA) co-polymer
particles by volume. DermaLive – 200 mg 45 –
65 micro beads, 14.4 mg HA. Dermadeep – 200 mg 80 – 110 micro beads,14.4 mg HA.
THE Aesthetic Guide Primary Care Edition Spring 2009 www.mi news.com
DERMAL FILLER PRODUCT COMPARISON Manufacturer Product(s) Description Physician Regulatory Status Component Fascia Biosystems
Human allograft material – fascia, collected
with sterile normal saline, 0.5% lidocaine.
are no off-label uses – hence aphysician can use as desired. FibroGen, Inc.
human collagen type III in saline with lido-
and safety study required forregulatory approval of FG-5017is expected to begin in 2005. FuHua High Molecular Matter Company, Ltd. FzioMed, Inc.
Non-permanent, long lasting, ultra smooth
dermal filler, containing no bacterial or ani-
mal by-products, no cross-linking chemicals
Isolagen, Inc.
Isolagen – autologous cellular system –
Laboratories
hyaluronic acid (2.1%) sodium chloride.
MacDermol R – Avian cross-linkedhyaluronic acid (3.4%) chitosan chondroitinsulfate sodium chloride. Pharmaceutical
NASHA gel – a non-animal hyaluronic acid,
stabilized with BDDE. The differentiation is in
the size of the NASHA particles, to assure a
Restylane Touch – 500,000 particles per ml.
Restylane – 100,000 particles per ml.
Restylane Perlane – 10,000 particles per ml.
Restylane Sub-Q – 1,000 particles per ml. Mentor Corporation in conjunction with
double cross-linked (DXL technology).
Puragen Plus contains lidocaine integrated
Corporation
0.3% lidocaine integrated directly into theformula. Merz Pharma GmbH & Co. KGaA
hyaluronic acid – via biofermentation –
Russia and Italy from Anteis SA. U.S. approval pending. Nordic Aesthetics
8.4 mg/ml, bi-phasic gel of cross-linked HA
(by S&V, Germany)
linked HA (CIS technology), 1 ml and 2 mlsyringes.
24 mg/ml, bi-phasic gel of cross-linked HA
micro-particles dispersed in non cross-linkedHA (CIS technology), 1 ml and 2 ml syringes.
24 mg/ml, biphasic gel of cross-linked HA
micro-particles dispersed in non cross-linkedHA (CIS technology), 0.5 ml and 1 ml syringes.
12 mg/ml, non cross-linked HA for skin reju-
venation and hydration, 2 ml syringe. Ortho Dermatologics Aesthetics
collagen – glycation with a natural sugar –
solution. Glymatrix technology provides a
collagen that extends the benefits for up to
THE Aesthetic Guide Primary Care Edition Spring 2009 www.mi news.com
DERMAL FILLER PRODUCT COMPARISON Manufacturer Product(s) Description Physician Regulatory Status Component Polymekon
BIO-ALCAMID – 96% water and 4% synthet-
ic reticulate polymer (poly-Alkyl-mide). Lips is
soft and compact. Face has the same com-position (it is not a dilution), Body has the
same consistency as the Face form, but con-
Bioinblue – PVA (polyvinyl alcohol 8%) andwater (92%). ProCytech SA
Evolution is a mixture of microscopic softspheres of polyvinyl in a viscoelastic gel ofpoly (acrylamide-co-DADMA) gel. Prollenium Medical Technologies
Revanesse Ultra – high viscosity, cross-linked, reticulated hyaluronic acid 25 mg,hypromellose 15 mg. ReDexis – cross-linked reticulated hyaluronicacid 25 mg, hypromellose 15 mg,dextronomer DEAE 25 mg.
NASHA gel – a non-animal hyaluronic acid,
stabilized with BDDE. The differentiation is in
the size of the NASHA particles, to assure a
Restylane Touch – 500,000 particles per ml.
Restylane – 100,000 particles per ml.
Restylane Perlane – 10,000 particles per ml.
Restylane Sub-Q- 1,000 particles per ml. Rofil / Philoderm
Rofilan – 20 mg/ml cross-linked hyaluronic acid. Sanofi-Aventis
Poly-L-Lactic acid (PLLA) hydrogel belonging
to the family of aliphatic polyesters.
tion and/or correction of thesigns of facial fat loss (lipoatro-phy). Approved in Europe in2000 as NewFill – 2004 asSculptra for facial aesthetic use.
100% hyaluronic acid-based, resorbable and
Laboratories
Teosyal KissTeosyal Ultra DeepTeosyal First LinesTeosyal Touch UpTeosyal Meso
Uroplasty
Solid silicone microspheres (100 to 400 and
600 µm) suspended in a polyvinylpyrrolidonevector.
THE Aesthetic Guide Primary Care Edition Spring 2009 www.mi news.com
Informative Article Lactic Acidosis In Critically Ill Patients Shafali Nandwani, *Mahip Saluja, **Mayank Vats ,**Yatin Mehta Department of Medicine, * Department of Pulmonary Medicine, Subharti Medical College, Meerut-250002, **Department of Pulmonary and Critical Care, Indraprastha Apollo Hospital, New Delhi-110044 Abstract: Lactic acidosis is defined as increase in blood lactate level
Sub-committee on economics and planning FOREWORD During its regular meetings the Sub-Committee on Economics and Planning of the Standing Committee of the Hospitals of the European Union (HOPE) deals with the developments regarding the health care systems of the member states. As a result of this the Sub-Committee delivered reports to HOPE’s Plenary Assembly on topics like planning, solidar